Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0CV7T
|
||||
Former ID |
DIB015873
|
||||
Drug Name |
Patamostat
|
||||
Synonyms |
E-3123
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Hypotension [ICD9: 458, 796.3; ICD10:I95] | Terminated | [545400] | ||
Company |
Eisai Co Ltd
|
||||
Structure |
Download2D MOL |
||||
Formula |
C20H20N4O4S
|
||||
Canonical SMILES |
N1(C(=O)CCC1=O)CCSc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1.S(=<br />O)(=O)(O)C
|
||||
CAS Number |
CAS 114568-32-0
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Trypsin | Target Info | Modulator | [533452], [549592], [550162] | |
WikiPathways | Activation of Matrix Metalloproteinases | ||||
References | |||||
Ref 533452 | Effects of E-3123, a new protease inhibitor, on several protease activities and on experimental acute pancreatitis. Nihon Yakurigaku Zasshi. 1988 May;91(5):285-93. | ||||
Ref 549592 | US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT. | ||||
Ref 550162 | EP patent application no. 2490711, A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.